Tetratherix LimitedASX: TTX

Line of sight ophthalmic tissue spacing US revenue

· Issued by Tetratherix Limited via ASX

Filed with ASX · · 4 pages · English

Summary by 6ix AI

Tetratherix Limited reports the successful completion of a preclinical evaluation for its Optimatrix product, designed for use in cataract surgery, demonstrating effective intraocular pressure management post-surgery. The study showed that even with the product remaining in the eye, pressure returned to pre-operative levels within a short timeframe, indicating its safety and efficacy. Optimatrix is a fully synthetic ophthalmic viscosurgical device that simplifies surgical procedures by eliminating the need for extensive removal processes.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Tetratherix Limited 2026Tissue Spacing FranchiseSUCCESSFUL COMPLETION INDEPENDENTOPTIMATRIX PRECLINICAL EVALUATIONAnchored by ScienceASX Release16 September 2026ASX:TTXHIGHLIGHTSSuccessful completion of the first preclinical performance study for Optimatrix in cataract surgery with a...

Tetratherix Limited on 6ix

Earlier from Tetratherix

Later from Tetratherix

All Tetratherix news releases